Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12889811 | 0.91 | CTSV (0.38) | KDM4ECTSVCTSLCTSBCTSS | |
| SCHEMBL3185516 | 0.86 | CTSV (0.40) | KDM4ECTSVCTSLCTSBCTSS | |
| SCHEMBL12890134 | 0.83 | CTSV (0.36) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL15119450 | 0.81 | CTSV (0.35) | KDM4ECTSVCTSLCTSBCTSS | |
| SCHEMBL12864078 | 0.81 | CTSV (0.35) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL8969283 | 0.77 | CTSV (0.38) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL26039152 | 0.77 | CTSV (0.38) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL5481927 | 0.75 | — | — | |
| SCHEMBL9197226 | 0.75 | — | — | |
| SCHEMBL15062108 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8936781-B2 | Macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, HAVCR2, DPP4 | KDM4E 1076/4885CTSV 11/4885CTSL 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.